N-Acetyl Selank Amidate is a modified version of Selank with N-acetylation and C-amidation for increased metabolic stability. Base Selank is approved in Russia for anxiety and cognitive disorders. This modified form is popular for intranasal use in the research peptide community.
Category: Nootropic / Anxiolytic. Evidence rating: C (early/mixed human evidence).
Clinical status: Research-only (base form approved in Russia)
Upregulates BDNF and NGF expression. Modulates GABAergic neurotransmission. Inhibits enkephalin degradation. Regulates IL-6 levels. The terminal modifications enhance resistance to peptidase degradation, potentially extending duration of action.
Safety considerations: Nasal irritation with intranasal use; Theoretical immune modulation effects.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-08-12.
Related peptides: Selank.
Compare: N-Acetyl Selank Amidate vs Selank.
It is based on the same peptide sequence but has chemical modifications (acetylation and amidation) at the termini that should improve stability and potentially duration of action.
N-Acetyl Selank Amidate is a modified version of Selank with N-acetylation and C-amidation for increased metabolic stability. Base Selank is approved in Russia for anxiety and cognitive disorders. This modified form is popular for intranasal use in the research peptide community.
On the PeptideAtlas A–F scale, N-Acetyl Selank Amidate is rated C (Early Evidence). Early human evidence, limited trials, or mixed findings
Research-only (base form approved in Russia)
Upregulates BDNF and NGF expression. Modulates GABAergic neurotransmission. Inhibits enkephalin degradation. Regulates IL-6 levels. The terminal modifications enhance resistance to peptidase degradation, potentially extending duration of action.